AZD-7624

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

AZD-7624 是一种有效的、选择性的吸入式 p38α MAPK 抑制剂，pIC50 为 10.0。

AZD-7624 is a potent, selective, inhaled p38α MAPK inhibitor with pIC50 of 10.0, displays 15-fold selectivity for p38α over p38β MAPK and >10,000-fold selectivity over p38γ and p38δ MAPK; inhibits LPS-induced TNF-α and IL-6 release in human alveolar macrophages pIC50 of 9.2 and 8.8, respectively; shows potential for prevention of exacerbations in COPD.COPD Phase 2 Discontinued.

AZD7624 is an inhaled p38 inhibitor, with potent anti-inflammatory activity. AZD7624 inhibits LPS-induced TNFα in human mononuclear cells, in whole blood as well as in alveolar macrophages in vitro, with pIC50s of 8.4, 8.1, and 9.0.

——

AZD7624

MAPK/ERK Signaling

p38 MAPK

p38 MAPK

Inflammation/Immunology

COPD

1095004-78-6

491.56

C27H30FN5O3

>98% (HPLC)

In Vitro:?DMSO : 62.5 mg/mL (127.15 mM)

O=C(NC1CC1)C2=CC(N3C(C(NC4(C5=CC=CC=C5OCCNC)CC4)=NC=C3)=O)=C(C)C(F)=C2

N-cyclopropyl-3-fluoro-4-methyl-5-(3-((1-(2-(2-(methylamino)ethoxy)phenyl)cyclopropyl)amino)-2-oxopyrazin-1(2H)-yl)benzamide

(-20℃)

With Ice Pack

≥ 2 years